Last updated on June 2018

A Repeated Dose-finding Study of Sarilumab in Children and Adolescents With Systemic Juvenile Idiopathic Arthritis (sJIA)

Brief description of study

Primary Objective: To describe the pharmacokinetic (PK) profile of sarilumab in patients with sJIA in order to identify the dose and regimen for continued development in this population. Secondary Objective: To describe: - The pharmacodynamic (PD) profile, the efficacy and the safety of sarilumab in patients with sJIA. - The long term safety of sarilumab in patients with sJIA.

Detailed Study Description

The total study duration per patient will be 114 weeks that will consist of a 4-week screening, a 12-week core treatment period, a 92-week extension phase, and a 6-week post-treatment follow-up.

Clinical Study Identifier: NCT02991469

Contact Investigators or Research Sites near you

Start Over

For site information, send an ...

Investigational Site Number 1520016
Concepcion, Chile